Predicting quality of life outcomes after subthalamic nucleus deep brain stimulation
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objectives: To examine disease, treatment, cognitive, and psychological factors associated with quality of life (QoL) before and after surgery and assess the ability to predict QoL outcomes.
Methods: We identified a retrospective, cross-sectional sample of 85 patients with Parkinson disease who underwent subthalamic deep brain stimulation (DBS). Patients' QoL was categorized as “improved” and “stable/worsened” using reliable change indices. Univariate correlational analyses identified relationships between Parkinson's Disease Questionnaire–39 ratings and disease (Unified Parkinson's Disease Rating Scale–III [UPDRS-III] motor scores on and off medications, disease duration), treatment (medication burden, unilateral vs bilateral DBS), cognitive (neuropsychological battery), and psychological (depression) variables. Step-wise multiple linear regression and logistic regression models included selected preoperative variables to predict change in QoL ratings and QoL outcome after surgery.
Results: Fifty-one percent of patients reported clinically significant improvements in QoL while 47% reported stable QoL and 2% worsened. Motor scores (UPDRS-III) were not relevant to QoL changes, potentially because of the rarity of poor motor outcomes, while single-trial learning and depression scores were the most important variables in predicting QoL changes. There was a subtle additional benefit to undergoing bilateral subthalamic nucleus DBS.
Conclusions: The findings provide greater insight into the nonmotor features that contribute to the success of subthalamic nucleus DBS procedures from the patient's perspective and raise questions about the treatment focus and emphasis on symptom profiles in DBS candidacy evaluations.
GLOSSARY
- BDI-II=
- Beck Depression Inventory–2nd edition;
- CI=
- confidence interval;
- DBS=
- deep brain stimulation;
- DRS-2=
- Dementia Rating Scale–2nd edition;
- OR=
- odds ratio;
- PD=
- Parkinson disease;
- PDQ-39=
- 39-item Parkinson's Disease Questionnaire;
- QoL=
- quality of life;
- STN=
- subthalamic nucleus;
- UPDRS-III=
- Unified Parkinson's Disease Rating Scale–III
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
- Received March 26, 2014.
- Accepted in final form July 30, 2014.
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulationR. Kumar, A.M. Lozano, E. Sime et al.Neurology, August 01, 1999 -
Article
Effects of deep brain stimulation on pain and other nonmotor symptoms in Parkinson diseaseRubens G. Cury, Ricardo Galhardoni, Erich T. Fonoff et al.Neurology, September 12, 2014 -
Articles
Subthalamic nucleus deep brain stimulation in primary cervical dystoniaJ.L. Ostrem, C.A. Racine, G.A. Glass et al.Neurology, March 07, 2011 -
Editorial
Subthalamic Nucleus Deep Brain StimulationUncomplicating Motor Complications for the Long HaulKelvin L. Chou, David Charles et al.Neurology, June 02, 2021